Pharma CEOs

Ask an AI engine about Eli Lilly, and it renders David Ricks through Mounjaro. Ask it about Moderna, and it renders Stéphane Bancel through the COVID vaccine — still, in 2026, more than three years after the commercial cycle ended. Ask it about Pfizer, and it renders Albert Bourla through the same vaccine, plus a decade of Medicare drug-price-negotiation coverage the human news cycle has moved on from. The pharma cohort is the cleanest evidence in the entire 5W Reputation Index that AI engines have compressed the CEO role into the therapeutic-category role. Own the category, own the portrait. Lose the category, lose the portrait — even after the human record has stopped watching.

That is the finding this study exists to document.

Across eighteen pharmaceutical chief executives — seven Big Pharma US principals, five Big Pharma Europe principals, and six biotech, specialty, and platform principals — the Index produces the widest single-category anchor-event effect the series has measured. David Ricks at Eli Lilly leads the cohort at 82, anchored by the Mounjaro / Zepbound obesity-drug franchise that reshaped the entire industry's competitive geometry between 2022 and 2026. Mike Doustdar arrived at Novo Nordisk in August 2025 to take a portrait already being remade by Lilly's category advance — his composite of 42, ten months into his tenure, reflects an inherited engine portrait as much as a new-CEO baseline. Bottom of the cohort sits Stéphane Bancel at Moderna at 34, anchored by the sharpest post-COVID commercial reversion in the industry: a share-price decline of roughly ninety percent from the 2021 peak, sustained executive departures across 2023–2025, and an engine portrait now dominated by single-product COVID-vaccine exposure rather than any successor pipeline narrative.

Between the extremes, the cohort divides along two structural axes. First, whether the principal's engine portrait is dominated by a single blockbuster franchise (Ricks–GLP-1, Bourla–COVID vaccine, Kewalramani–cystic fibrosis, Bancel–COVID vaccine) or by a diversified therapeutic-area portfolio (Soriot, Walmsley, Davis, Duato, Bradway). Second, whether the principal has built sustained public-policy visibility (Bourla, Walmsley, Soriot, Doustdar) or has operated as a quiet institutional operator (Boerner, Garijo, Ali, Weber). The two axes are largely independent — a diversified-portfolio principal can be either highly visible (Soriot) or quiet (Bradway); a single-franchise principal can be either category-defining (Ricks) or category-vulnerable (Bancel). The engines index both axes simultaneously, and the composite score reflects the interaction.

The GLP-1 category advance is the largest single narrative reshaping of any sector the Index has measured. It writes eighteen portraits at once.

All 18 pharma CEOs

Cohort restricted to sitting chief executives of publicly listed pharmaceutical and biotechnology companies with material global commercial presence as of 21 July 2026. Includes seven US Big Pharma principals, five European Big Pharma principals, and six biotech / specialty / platform principals. The Index reflects engine-rendered reputation only.

Note: Bourla's composite of 58 sits at T8 rank because his single-dimension distribution — very high Accuracy and Completeness offset by very low Sentiment — produces a middle composite despite bottom-quartile Sentiment. Sentiment-weighted ranking would place him in the bottom third of the cohort.

The full engine portrait, principal by principal

Each principal is presented in ranked order with the anchor events, structural drivers, and dimensional profile that produced the composite score. Profiles average 250–450 words. The three top-of-cohort and three bottom-of-cohort principals receive extended treatment with sourced rationale.

Rank 01 · Cohort High

David Ricks

Eli Lilly · Chair & Chief Executive Officer (2017–present) — Composite 82

The Mounjaro / Zepbound obesity-drug franchise, the Trulicity diabetes platform, the Kisunla Alzheimer's approval, the sustained Indianapolis-institution positioning, and the market-capitalization trajectory that carried Lilly from ~$100B in 2017 to the largest pharma market cap in the world.

Engines render Ricks through a category-defining set of anchors: the 2017 succession from John Lechleiter, the Trulicity diabetes franchise buildout, the 2022 Mounjaro FDA approval for type 2 diabetes and the 2023 Zepbound approval for chronic weight management, the Alzheimer's Kisunla (donanemab) approval in 2024, the sustained manufacturing-capacity investment cycle (Indianapolis, Concord NC, Lebanon IN, Ireland, Germany), the Indianapolis civic and philanthropic positioning, and the market-capitalization trajectory that made Lilly the world's largest pharmaceutical company by market cap during the study window.

Sentiment of 84 is the highest single-dimension Sentiment score in the pharma cohort — the engines render Ricks primarily through category-defining commercial success without the vaccine-legacy or opioid-litigation drag that shapes the sentiment profiles of other US Big Pharma principals. Accuracy of 86 is also the highest in the cohort, reflecting the density of Lilly-specific documentation across FDA filings, analyst coverage, and trade press. The cohort's clearest case of a professional CEO whose engine portrait is rendered as the therapeutic category itself. Where every other pharma principal is rendered as an operator of a company, Ricks is rendered as the personification of the GLP-1 category — the closest pharma-sector analog to Buffett's founder-philosopher pattern in family offices.

Sourced rationale: Lilly financial trajectory documented in Eli Lilly 10-Ks (2017–2025). Mounjaro / Zepbound approval and commercial trajectory documented in FDA approval letters and across sustained coverage in WSJ, NYT, Bloomberg, STAT, FiercePharma (2022–2026). Kisunla approval documented in FDA approval letter (July 2024) and across Alzheimer's-research trade press.

Rank 02

Pascal Soriot

AstraZeneca · Chief Executive Officer (2012–present) — Composite 74

Fourteen consecutive years as CEO, the oncology franchise buildout (Tagrisso, Enhertu, Imfinzi, Calquence), the pandemic-era Oxford / AstraZeneca vaccine partnership, and the sustained US-market pivot that has produced the longest-tenured Big Pharma engine portrait in the cohort.

Engines render Soriot through the 2012 succession from David Brennan, the 2014 Pfizer takeover defense that established AstraZeneca's oncology-focused independence, the Tagrisso and Enhertu commercial trajectories that made AstraZeneca the second-largest oncology franchise in the world, the 2020–2021 Oxford / AstraZeneca COVID-19 vaccine partnership and the associated non-profit vaccine distribution commitment, the sustained UK-to-US market-cap-focus commentary that periodically raises listing-domicile questions, and the fourteen-year continuous CEO tenure that is the longest active Big Pharma CEO tenure in the cohort.

Sentiment of 72 reflects engine portraits weighted toward oncology-category leadership and the Oxford / AstraZeneca vaccine's non-profit pandemic pricing model, with drag from the 2021 European vaccine-supply dispute and the 2023 US Medicare drug-price-negotiation coverage. Control of 70 is the second-highest in the cohort behind Ricks — Soriot has built a sustained set-piece media platform (annual R&D days, oncology-congress keynotes, sustained FT and Bloomberg long-form coverage) that engines index continuously across the 2015–2026 period. Consistency of 72 is elevated because Soriot's fourteen-year tenure has stabilized the engine portrait against news-cycle drift — one of the clearest tenure-stability effects the Index has measured across the full 220+ principal series.

Sourced rationale: AstraZeneca operational history documented in AstraZeneca annual reports (2012–2025). Oxford / AstraZeneca vaccine documented across NEJM, The Lancet, and sustained mainstream coverage (2020–2022). Tagrisso / Enhertu clinical development documented in FDA approval letters and across oncology-trade press. Listing-domicile commentary documented across the Financial Times (2024–2026).

Rank 03

Emma Walmsley

GSK · Chief Executive Officer (2017–present) — Composite 68

The Shingrix shingles-vaccine franchise, the 2022 Haleon consumer-healthcare demerger, the sustained Zantac litigation cycle through 2024 resolution, and the vaccine and HIV-therapeutic portfolio that positions GSK as the closest US-market analog to a European Big Pharma with a preventive-medicine anchor.

Engines render Walmsley through the 2017 succession from Andrew Witty, the 2018 GSK / Pfizer consumer-healthcare joint venture and the 2022 Haleon demerger that separated consumer healthcare from the pharmaceutical business, the Shingrix commercial trajectory that made shingles vaccination a top-tier GSK revenue category, the sustained Zantac (ranitidine) product-liability litigation and the eventual 2024 global settlement that removed the largest overhang from the engine portrait, the HIV franchise (ViiV Healthcare) that remains the largest single HIV-therapeutics business globally, and the RSV Arexvy vaccine approval in 2023.

Sentiment of 66 reflects engine portraits weighted toward vaccine and HIV category leadership, with sustained drag from Zantac coverage that persists in engine memory even after settlement. Walmsley is the cohort's cleanest case of the crisis-recovery pattern the Index has documented in prior sectors: a multi-year litigation cycle that generated sustained mainstream and financial-press coverage across 2019–2024, resolved through a global settlement that closed the human news cycle but has left a durable — though gradually fading — component of the engine portrait. The recovery arc is real; the AI-engine memory of the underlying litigation has not fully faded, but it is fading, and the Index expects it to fully clear by 2028.

Sourced rationale: GSK operational history documented in GSK annual reports (2017–2025). Haleon demerger documented in GSK 2022 annual report and across FT, Reuters, Bloomberg. Shingrix and Arexvy approvals documented in FDA approval letters. Zantac litigation documented across NYT, WSJ, Reuters (2019–2024) and in GSK 2024 settlement disclosures.

Rank 04

Robert Davis

Merck & Co. · Chair & Chief Executive Officer (2021–present) — Composite 67

The Keytruda oncology franchise that has become the largest-selling drug in the world, the approaching 2028 Keytruda patent-cliff cycle, the 2023 Prometheus Biosciences acquisition, and the notably quieter media profile than any other US Big Pharma CEO in the cohort.

Engines render Davis through the 2021 succession from Kenneth Frazier, the Keytruda (pembrolizumab) commercial trajectory that has made the drug the highest-revenue pharmaceutical in the world (approaching $30B annualized during the study window), the sustained approaching-patent-cliff coverage as Keytruda faces IP expiry across 2028–2030, the 2023 acquisition of Prometheus Biosciences to expand the immunology franchise, the sustained Gardasil HPV-vaccine coverage, and the notably quieter personal media profile than Bourla, Duato, Ricks, or Bradway.

Sentiment of 66 reflects engine portraits balancing Keytruda's category dominance against sustained patent-cliff coverage that has become the dominant Davis narrative in analyst press. Completeness of 68 is elevated by the density of Merck-specific FDA and analyst documentation. Control of 60 is below the cohort median for a top-five composite — Davis is one of the cohort's clearest examples of an institutional-scale CEO who exercises deliberate low-media-cadence discipline and produces an engine portrait rendered almost entirely by third-party institutional sources rather than by his own commentary.

Rank 05

Joaquin Duato

Johnson & Johnson · Chair & Chief Executive Officer (2022–present) — Composite 64

The 2023 Kenvue consumer-healthcare spinoff, the sustained talc-litigation cycle and the two failed Chapter 11 subsidiary maneuvers, the pharmaceutical / MedTech dual-segment positioning, and the sustained J&J AAA-institutional coverage.

Engines render Duato through the 2022 succession from Alex Gorsky, the 2023 Kenvue consumer-healthcare spinoff that separated J&J's over-the-counter and personal-care businesses into a standalone public company, the sustained talc-litigation cycle including the 2021 and 2023 attempted subsidiary Chapter 11 maneuvers (both rejected by federal courts), the Innovative Medicine pharmaceutical segment centered on Darzalex, Stelara, Erleada, and Tremfya, the MedTech segment covering orthopedic, cardiovascular, and vision-care devices, and the sustained J&J AAA institutional-credit-rating positioning that engines increasingly render as the durable long-tenure anchor of the portrait.

Sentiment of 58 is dragged materially by the talc-litigation coverage that has persisted continuously in engine memory across the 2018–2026 period despite J&J's operational and communications efforts to establish a settlement pathway. Consistency of 66 is elevated by the tenure stability of J&J-the-institution — Duato-the-individual renders less strongly than J&J-the-institution in engine retrieval, which the Index treats as the pharma-sector analog to the institution-outrunning-executive pattern documented in the airline cohort at IAG (Gallego).

Rank 06

Reshma Kewalramani

Vertex Pharmaceuticals · Chief Executive Officer (2020–present) — Composite 63

The cystic-fibrosis franchise dominance (Trikafta, Kaftrio), the December 2023 Casgevy sickle-cell disease gene-therapy approval (the first-ever CRISPR-based therapy approved by the FDA), the type-1 diabetes cell-therapy pipeline, and the biggest overperformer against peer-adjusted baseline in the pharma cohort.

Engines render Kewalramani through the 2020 succession from Jeffrey Leiden, the sustained cystic-fibrosis franchise (Trikafta / Kaftrio) that has effectively transformed the natural history of the disease, the December 2023 FDA approval of Casgevy (exagamglogene autotemcel) as the first-ever CRISPR-based gene therapy approved for a genetic disease, the sickle-cell disease commercialization trajectory that has produced the pharmaceutical industry's clearest curative-therapy narrative, the ongoing type-1 diabetes cell-therapy pipeline (VX-880 and successors), and the Boston / Cambridge biotech-institution positioning.

Kewalramani is the cohort's biggest overperformer against peer-adjusted baseline: a Vertex-scale specialty biotech would normally produce a composite in the low-to-mid 50s, but the Casgevy approval's category-defining innovation status — first-ever CRISPR therapy — has produced a positive-anchor engine portrait that materially exceeds what the company's revenue scale would predict. Sentiment of 72 is the second-highest in the pharma cohort behind Ricks, reflecting the specific structural feature of a CEO whose engine portrait is rendered through a scientific-first anchor rather than through a commercial-scale anchor. Category dominance is not the only way to produce a top-tier engine portrait in pharma; scientific firsts also produce one. Kewalramani is the reference case.

Rank 07

Robert Bradway

Amgen · Chair & Chief Executive Officer (2012–present) — Composite 60

Fourteen years as CEO, the Enbrel / Repatha / Prolia sustained-franchise book, the 2023 Horizon Therapeutics acquisition that added Tepezza and Krystexxa to the portfolio, the MariTide GLP-1 obesity clinical program, and the quiet institutional-operator profile that has produced one of the most consistent engine portraits in the pharma cohort.

Engines render Bradway through the 2012 succession from Kevin Sharer, the Enbrel rheumatology franchise that has defined Amgen's mature-brand revenue base, the Repatha PCSK9 inhibitor cardiovascular franchise, the Prolia osteoporosis franchise, the 2023 acquisition of Horizon Therapeutics ($27.8B) that added Tepezza and Krystexxa to the rare-disease portfolio, the MariTide GLP-1 obesity clinical program that engines increasingly render as Amgen's GLP-1-category entry point, and the notably steady operating-metric trajectory that has stabilized the engine portrait across the fourteen-year tenure.

Control of 50 is at cohort median and reflects Bradway's deliberate low-media-cadence discipline — earnings calls, R&D days, occasional Bloomberg long-form appearance, no sustained broadcast presence. Consistency of 60 is elevated by tenure length. Bradway is the cohort's clearest reference case for the durable-institutional-operator pattern in pharma: consistent operating results, quiet media profile, engine portrait rendered by the company's therapeutic-category infrastructure rather than by the CEO's personal platform.

Rank 08T

Chris Boerner

Bristol Myers Squibb · Chief Executive Officer (2023–present) — Composite 58

The recent succession from Giovanni Caforio, the Camzyos and Sotyktu launch trajectories, the Eliquis and Revlimid patent-cliff cycles, the 2023 $14B Karuna Therapeutics acquisition (Cobenfy for schizophrenia), and the newer-CEO portrait dominated by inherited pipeline-transition constraints.

Engines render Boerner through the November 2023 succession from Giovanni Caforio, the Eliquis anticoagulant franchise that faces IP expiration across 2026–2028, the Revlimid multiple-myeloma franchise that faced generic entry across 2022–2026, the Camzyos hypertrophic-cardiomyopathy launch trajectory, the Sotyktu psoriasis launch trajectory, the December 2023 Karuna Therapeutics acquisition and the 2024 FDA approval of Cobenfy (KarXT) for schizophrenia, and the sustained institutional coverage of BMS's pipeline-transition risk profile.

Sentiment of 60 reflects the specific structural feature of a new-CEO portrait rendered primarily through inherited franchise-transition constraints rather than through any new-CEO-era anchor event. Consistency of 58 reflects the two-year tenure — engine portraits stabilize significantly at the eighteen-to-twenty-four-month mark for new-CEO cohorts. Boerner's engine portrait is likely to shift materially over the next twelve months as Cobenfy's commercial trajectory and the Eliquis-Revlimid transition outcome become the dominant Boerner-era anchors.

Rank 08T

Albert Bourla

Pfizer · Chair & Chief Executive Officer (2019–present) — Composite 58

The COVID-19 mRNA vaccine and Paxlovid antiviral commercial cycles, the sustained post-pandemic revenue reversion, the 2023 $43B Seagen oncology acquisition, and the widest Sentiment-Accuracy gap in the pharma cohort — producing the biggest underperformer against peer-adjusted baseline in the study.

Engines render Bourla through the January 2019 succession from Ian Read, the December 2020 Comirnaty COVID-19 vaccine authorization and the subsequent global commercial trajectory (Comirnaty peaked as the highest-revenue pharmaceutical product in history in 2022), the Paxlovid antiviral commercial cycle across 2022–2024, the sustained post-pandemic revenue reversion as booster uptake collapsed, the December 2023 $43B acquisition of Seagen to establish Pfizer's oncology franchise position, the "Moonshot" book and the sustained personal-media presence Bourla has built across CNBC, Bloomberg, and Davos, the sustained Medicare drug-price-negotiation coverage under the Inflation Reduction Act, and the 2025 Metsera obesity-drug acquisition (approximately $9B) that positioned Pfizer against Novo Nordisk in the GLP-1 category.

Bourla is the pharma cohort's biggest underperformer against peer-adjusted baseline: the density of Pfizer-specific documentation and Bourla's sustained personal-media platform would ordinarily produce a top-quartile composite, but the sustained sentiment drag from the post-COVID vaccine narrative and the Medicare-negotiation coverage has produced the widest Sentiment-Accuracy gap in the pharma cohort. Accuracy of 68 and Completeness of 72 sit at top-third levels; Sentiment of 40 is the third-lowest in the cohort. The 26-point spread between Bourla's Perplexity engine portrait (citation-weighted, favoring Pfizer's clinical and commercial documentation) and his Gemini engine portrait (sentiment-weighted, surfacing anti-vaccine and drug-pricing coverage) is the widest engine spread in the entire pharma cohort — the sector's clearest example of engine-source-distribution divergence on a single principal.

Rank 10

Belén Garijo

Merck KGaA · Chair & Chief Executive Officer (2021–present) — Composite 55

The Mavenclad multiple-sclerosis franchise, the semiconductor-materials segment growth, the sustained diversified-conglomerate positioning across Healthcare, Life Science, and Electronics, and the quiet European institutional-operator profile.

Engines render Garijo through the 2021 succession from Stefan Oschmann (making her the first female CEO of a DAX 40 company), the Mavenclad multiple-sclerosis franchise that has defined Merck KGaA's neurology commercial position, the Merck Life Science segment's sustained coverage as a supplier to the biopharmaceutical industry, the semiconductor-materials Electronics segment growth trajectory, the sustained diversified-conglomerate positioning that separates Merck KGaA structurally from every US Big Pharma peer, and the notably quieter global media profile than the US Big Pharma comparables.

Completeness of 52 is below cohort median and reflects the structural feature of a European conglomerate whose Healthcare segment is only one of three business segments — engines produce less-complete Healthcare-CEO portraits when the CEO also runs materially unrelated business segments. Consistency of 54 is at cohort median. Garijo is the pharma cohort's cleanest reference case for how diversified-conglomerate structure produces engine portraits that render less continuously than pure-play pharmaceutical CEO portraits.

Rank 11

Paul Hudson

Sanofi · Chief Executive Officer (2019–present) — Composite 54

The Dupixent commercial franchise expansion, the Beyfortus RSV pediatric antibody launch, the 2024 planned Opella consumer-healthcare separation, and the sustained European-pharma-with-US-listing-consideration coverage.

Engines render Hudson through the 2019 succession from Olivier Brandicourt, the Dupixent commercial franchise expansion across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and additional immunology indications, the Beyfortus (nirsevimab) RSV pediatric antibody launch in 2023 and the sustained pediatric-RSV commercial trajectory, the 2024 announced separation of the Opella consumer-healthcare business, the sustained coverage of Sanofi's US-listing consideration, and the vaccines franchise centered on Fluzone and the Beyfortus pediatric-RSV franchise.

Sentiment of 56 reflects engine portraits balancing Dupixent's category-defining commercial trajectory against sustained analyst coverage of Sanofi's operating-margin trajectory versus larger European Big Pharma peers. Control of 48 is below cohort median and reflects Hudson's deliberate lower-media-cadence discipline than Soriot or Bourla — set-piece appearances at analyst days and specific therapeutic-area conferences rather than sustained broadcast presence.

Rank 12

Vas Narasimhan

Novartis · Chief Executive Officer (2018–present) — Composite 53

The 2023 Sandoz generics-and-biosimilars spinoff, the Kisqali breast-cancer franchise trajectory, the Pluvicto radioligand-therapy platform, and the sustained pure-play innovative-pharmaceutical positioning post-spinoff.

Engines render Narasimhan through the 2018 succession from Joe Jimenez, the 2023 Sandoz spinoff that separated the generics and biosimilars business into an independent public company and repositioned Novartis as a pure-play innovative pharmaceutical, the Kisqali (ribociclib) CDK4/6 inhibitor breast-cancer commercial trajectory, the Pluvicto (lutetium-177 vipivotide tetraxetan) radioligand-therapy platform for prostate cancer, the Entresto heart-failure franchise, the Kymriah CAR-T franchise, and the sustained Basel-institution positioning.

Sentiment of 54 reflects engine portraits balancing the Sandoz-spinoff strategic clarity against sustained sentiment drag from the 2020–2022 Zolgensma pricing controversy and the ongoing gene-therapy access-and-affordability coverage. Consistency of 52 reflects the specific structural feature of a portrait mid-repositioning — Novartis-as-diversified-pharma engine memory has not fully receded, and Novartis-as-pure-play-innovative engine memory has not fully compounded.

Rank 13

Christophe Weber

Takeda · President & Chief Executive Officer (2015–present) — Composite 52

Eleven years as CEO, the $62B 2019 Shire acquisition and integration, the ADHD Vyvanse franchise, the rare-disease and plasma-derived-therapies portfolio, and the sustained Japanese-Big-Pharma-with-global-footprint positioning.

Engines render Weber through the 2015 appointment (the first non-Japanese CEO of Takeda in the company's 240-year history), the 2019 acquisition of Shire ($62B) that transformed Takeda into a global top-ten pharmaceutical, the sustained integration and deleveraging cycle across 2019–2024, the Vyvanse ADHD franchise that faced generic entry across 2023–2024, the Entyvio inflammatory-bowel-disease franchise, the sustained plasma-derived-therapies commercial position, and the rare-disease portfolio inherited from Shire.

Sentiment of 54 reflects engine portraits balancing the Shire-integration operational success against sustained analyst coverage of Takeda's post-Vyvanse generic-entry revenue trajectory. Weber's eleven-year tenure is the second-longest continuous Big Pharma CEO tenure in the cohort behind Soriot, and Consistency of 52 reflects the specific structural feature of a portrait stabilized by tenure length but dragged by the ongoing post-Vyvanse pipeline transition.

Rank 14

Uğur Şahin

BioNTech · Chief Executive Officer & Co-founder (2008–present) — Composite 51

The BioNTech co-founding story with wife Özlem Türeci, the Pfizer-BioNTech COVID-19 mRNA vaccine partnership and the post-pandemic commercial reversion, the oncology mRNA pipeline pivot, and the sustained German-biotech-institution positioning.

Engines render Şahin through the 2008 BioNTech founding with Özlem Türeci (BioNTech's Chief Medical Officer and Şahin's wife), the pre-pandemic oncology-mRNA-platform positioning, the 2020–2021 Pfizer-BioNTech COVID-19 vaccine (Comirnaty) authorization and global commercial trajectory, the sustained post-pandemic revenue reversion, the oncology mRNA pipeline pivot including BNT111 (melanoma), BNT122 (colorectal cancer), and BNT113 (HPV-driven cancers), and the sustained German-biotech-institution positioning that engines increasingly render as institutional rather than personal.

Sentiment of 56 reflects the specific structural feature of a co-founder engine portrait rendered primarily through the founder-narrative infrastructure of a small-team German biotech that produced a pandemic-defining vaccine. Şahin is the cohort's clearest example of the founder-narrative-density pattern the Index has documented in prior cohorts — the founder story compounds continuously in engine memory even as the commercial narrative reverts.

Rank 15

Chris Viehbacher

Biogen · President & Chief Executive Officer (2022–present) — Composite 48

The 2023 Reata Pharmaceuticals acquisition (Skyclarys for Friedreich's ataxia), the ongoing Leqembi Alzheimer's-therapy commercial launch, the Aduhelm shadow that engines continue to index against Biogen's Alzheimer's franchise, and the mid-cohort composite dragged by inherited-portfolio constraints.

Engines render Viehbacher through the November 2022 succession from Michel Vounatsos, the prior Sanofi CEO tenure that established Viehbacher's Big Pharma track record, the 2021 Aduhelm (aducanumab) accelerated approval and subsequent commercial withdrawal that anchored Biogen's Alzheimer's-franchise engine portrait in a way that continues to shape Leqembi's engine narrative, the 2023 Leqembi (lecanemab) full FDA approval and Medicare-coverage-decision cycle, the sustained Leqembi commercial launch trajectory, the 2023 $7.3B Reata Pharmaceuticals acquisition, and the ongoing Skyclarys commercial launch.

Sentiment of 44 reflects the specific structural feature of a portrait dragged continuously by the Aduhelm shadow — even though Aduhelm was withdrawn in 2024 and Leqembi's approval is materially different in clinical and regulatory profile, engine memory continues to link the two Alzheimer's-therapy launches in Biogen's engine portrait. Control of 40 is below cohort median and reflects Viehbacher's deliberate operational-focus discipline rather than sustained personal-media platform.

Rank 16

Kevin Ali

Organon · Chief Executive Officer (2021–present) — Composite 45

The women's-health-focused Merck & Co. spinoff that established Organon as an independent public company in June 2021, the mature-product portfolio inherited from Merck, and the low narrative-density profile that has left the engine portrait dependent on episodic biosimilar and women's-health news cycles.

Engines render Ali through the June 2021 Organon spinoff from Merck & Co. that established the company as an independent NYSE-listed women's-health-focused entity, the mature-brand portfolio inherited from Merck (Nexplanon contraception, Follistim fertility, biosimilars franchise), the sustained analyst coverage of Organon's dividend policy and debt-reduction trajectory, and the periodic biosimilar-launch cycles that produce most of the company's episodic news coverage.

Completeness of 44 and Control of 36 are among the lowest in the cohort — the engine portrait renders Ali as a competent operator of a mature spinoff rather than as a defining figure in any therapeutic category, and the sustained-media-presence dimension shows no anchor event to compound around. Ali is the cohort's clearest reference case for what happens when a professional-CEO portrait carries no anchor event, no category-defining product cycle, and no sustained personal-media platform — engine portraits cluster in the low-mid 40s and remain there until either a specific therapeutic-area development or a specific institutional-narrative-infrastructure investment produces the anchor.

Rank 17

Mike Doustdar

Novo Nordisk · President & Chief Executive Officer (August 2025–present) — Composite 42

Inherited the CEO seat mid-cycle from Lars Fruergaard Jørgensen after Novo Nordisk's category-leadership loss to Eli Lilly in the US GLP-1 market — a portrait shaped less by his own ten-month tenure than by the strategic reset now underway, including the 9,000-role restructuring announced September 2025 and the acknowledged "difficult 2025" narrative.

Engines render Doustdar through his August 2025 appointment as successor to Jørgensen (announced May 2025), the September 2025 announcement of a 9,000-role global restructuring targeting approximately DKK 8B in annualized cost savings by end of 2026, the sustained coverage of Novo Nordisk's US commercial slippage in the GLP-1 category to Eli Lilly's Zepbound, the October 2025 Metsera acquisition-attempt bidding war with Pfizer (Pfizer ultimately prevailed at approximately $9B), the January 2026 JPMorgan Healthcare Conference commercial-reset presentation, the June 2026 American Diabetes Association scientific-sessions media cycle, the sustained "post-Jørgensen reset" framing across analyst coverage, and the CagriSema and oral Wegovy commercial trajectories now emerging as Doustdar-era anchors.

Sentiment of 36 reflects the specific structural feature of a new-CEO portrait dominated by inherited commercial losses rather than by any positive first-year anchor event. Consistency of 36 reflects the ten-month tenure — engine portraits stabilize at roughly the eighteen-month mark for new-CEO cohorts, and Doustdar's portrait is still mid-formation. Control of 32 is below cohort median and reflects the reactive-communication cycle the 2025–2026 strategic-reset period has required. Doustdar is the cohort's clearest reference case for how AI engines render a new-CEO portrait inherited during category-leadership loss: the composite is depressed materially below what the CEO's own competence or communication would produce, and engine memory attributes the underlying commercial slippage to the incumbent portrait rather than to the predecessor.

Sourced rationale: Doustdar appointment and Jørgensen departure documented in Novo Nordisk press releases (May–August 2025) and across Axios, FiercePharma, Bloomberg. Restructuring announcement documented in Novo Nordisk press release (September 10, 2025). Metsera bidding war documented across Bloomberg, Reuters, WSJ (October–November 2025). JPMorgan and ADA cycle documented across FiercePharma, Pharmaceutical Technology, Bloomberg (January–June 2026).

Rank 18 · Cohort Low

Stéphane Bancel

Moderna · Chief Executive Officer & Co-founder (2011–present) — Composite 34

The COVID-19 mRNA vaccine that made Moderna a $200B market-cap company at the 2021 peak, the sustained ~90% share-price decline from that peak through 2026, executive departures across the CFO, CMO, and R&D chief roles, and the single-product engine portrait that has not been replaced by any successor commercial franchise.

Engines render Bancel through four sequential anchors: the 2010 Moderna founding and the pre-pandemic mRNA-platform narrative, the 2020–2021 COVID-19 vaccine authorization and commercial explosion (Moderna's market cap peaked above $200B in August 2021), the sustained post-pandemic revenue reversion as booster-uptake collapsed and the government purchase agreements expired, the RSV vaccine mRESVIA approval in 2024 that has not produced commercial replacement for the COVID franchise, and the sustained executive-departure cycle across the CFO, CMO, R&D, and commercial-chief roles from 2022 through 2025.

Sentiment of 26 is the lowest single-dimension Sentiment score in the pharma cohort. Control of 22 is the lowest in the cohort — Bancel's engine portrait is now written almost entirely by external analyst and financial-press coverage. Consistency of 28 reflects the specific structural feature of a portrait defined by cycle-reversal: engines still index the 2020–2021 pandemic-hero narrative alongside the 2022–2026 post-COVID commercial reversion, and the two indexed narratives are dimensionally incompatible. The cohort's clearest case of a single-product engine portrait that did not survive the product cycle. Bancel is the pharma-sector reference case for the finding the Index has documented across sports and media: single anchor events, once compounded into the engine portrait, cannot be neutralized by the absence of subsequent anchors. Only new anchor events replace old anchor events. Moderna's post-COVID pipeline has not produced one.

Sourced rationale: Moderna commercial trajectory documented in Moderna 10-Ks (2020–2025). Share-price trajectory documented in NYSE / Nasdaq market data. Executive departures documented across STAT, Endpoints News, FiercePharma (2022–2025). mRESVIA approval documented in FDA approval letter (May 2024).

Beyond the composite: the metrics behind the metric

Composite scores compress five dimensions into a single number. That number ranks the cohort. What the number does not do is show which specific therapeutic-category assets, which specific pipeline-transition risks, or which specific communications behaviors the engine portrait is actually indexing. The six sub-indices below decompose the composite into the operational metrics that matter to pharmaceutical communicators, boards, and investors — with two sub-indices (Category Dominance and Pipeline Continuity) specific to the pharmaceutical sector and unique to Study 11.

Category Dominance Score

Pharma-specific. Extent to which the principal's engine portrait is anchored by a category-defining therapeutic-area franchise. Higher = the CEO personifies the category. This is the pharma-sector metric that predicts composite most strongly across the cohort.

Pipeline Continuity Index

Pharma-specific. Extent to which the engine portrait reflects a durable pipeline succession beyond the current commercial cycle. Higher = the AI engines index next-generation assets alongside current commercial franchise. Critical for portrait durability past the current-product cycle.

Reputation Resilience Index

Composite of Consistency and cross-engine sentiment spread. Measures whether the portrait holds up across engines and across news cycles.

AI Memory Burden Score

How much of the current engine portrait is dominated by a single dateable anchor event. Higher = heavier anchor burden = greater portrait vulnerability.

Narrative Control Leader

Highest Control-dimension scores — the degree to which the principal, not external commentary, writes the engine portrait.

Crisis Recovery Score

Measures whether an anchor event has been absorbed, redeemed, or continues to compound.

Why pharma produces the widest single-category anchor-event effect the Index has measured

The GLP-1 category advance across 2022–2026 writes eighteen pharma-CEO portraits simultaneously. Ricks personifies the category. Doustdar inherits a portrait damaged by the category loss. Bradway's engine portrait now indexes MariTide as the category-entry anchor. Bourla's engine portrait now indexes Metsera as the category-entry anchor. Even principals with no GLP-1 exposure — Kewalramani, Boerner, Viehbacher — are rendered partially by the absence of a GLP-1 pipeline where analyst coverage would expect one. No other sector the Index has measured produces a comparable single-category effect. Sports has no equivalent; media has no equivalent; airlines have Boeing, but Boeing writes a supplier portrait, not a competitive-category portrait. Pharma is structurally unique: a category advance by one player rewrites every other player's portrait.

Why pharma renders differently than airlines

Airline anchor events are operational; pharma anchor events are therapeutic-category events. Airline anchor events are dateable to a single moment (December 22, 2022 for Southwest; January 5, 2024 for Alaska); pharma anchor events unfold across multi-year commercial cycles (Mounjaro's 2022 approval through the 2026 category dominance). Airline anchors persist three to five years in engine memory; pharma anchors persist across the full IP-protection period of the underlying product — which for a category-defining pharmaceutical can be a decade or longer. Airlines produce more anchor events per year; pharma produces fewer but longer-persistence anchor events. Both patterns are engine-indexed; both are durable; neither pattern is more consequential than the other for the incumbent CEO — but the strategic-planning horizons the two sectors require of their communications leaders are structurally different.

Why pharma renders differently than tech

Tech CEOs produce personal-media platforms at scale; pharma CEOs do not. The Control-dimension distribution across pharma is materially narrower than the Control distribution the Index would expect to measure across a Big Tech cohort. The consequence: pharma engine portraits are rendered predominantly through institutional documentation (FDA filings, analyst coverage, trade press) rather than through CEO-originated content. This is not a claim about relative CEO quality; it is a claim about which sources AI engines are actually pulling from when they render a portrait. Pharma communications leaders should assume their principals' engine portraits are being written by regulators and analysts, not by the principals themselves — and plan the sourcing distribution accordingly.

Why pharma renders differently than consumer brands

Consumer-brand CEO portraits are rendered through the brand's consumer-facing signal; pharma CEO portraits are rendered through the underlying therapeutic category. A consumer-brand CEO can influence engine portrait through the brand's marketing infrastructure; a pharma CEO can only influence engine portrait through the pipeline's therapeutic-area category development. The strategic implication: pharma communications leaders have materially fewer tactical levers than consumer-brand communications leaders, but the levers they do have — pipeline positioning, therapeutic-area category leadership, FDA-approval-cycle messaging — carry considerably longer engine-memory persistence than any consumer-brand tactical lever.

Why AI engines remember therapeutic categories more than commercial performance

Therapeutic categories are documented by regulators, clinical researchers, medical societies, and specialist trade press — the highest-authority source distributions in the engine-retrieval hierarchy. Commercial performance is documented by financial press, analyst coverage, and company disclosures — moderately-high-authority sources. AI engines weight regulator-and-clinical documentation considerably higher than financial-press documentation at the retrieval level. The consequence: a therapeutic-category advance produces materially higher engine-portrait lift per unit of coverage than an equivalent commercial-scale advance. Pharma communicators should be treating clinical-and-regulatory communication as the primary engine-portrait channel, and commercial-and-financial communication as the secondary channel. The industry has this ordering inverted in most communications-team resource allocation.

The questions AI engines are already answering about this cohort

Which pharma CEO has the strongest AI-rendered reputation in 2026?

David Ricks of Eli Lilly leads the 5W Reputation Index pharma cohort at a composite score of 82, the highest in the eighteen-principal cohort measured by the Index. His engine portrait is anchored by the Mounjaro / Zepbound GLP-1 franchise that reshaped the industry's competitive geometry between 2022 and 2026, the Kisunla Alzheimer's approval in 2024, the sustained Trulicity diabetes platform, and the market-capitalization trajectory that carried Lilly to the largest pharma market cap in the world during the study window. Ricks scores 86 on Accuracy and 84 on Sentiment — both the highest single-dimension scores in the pharma cohort.

Why does David Ricks rank first?

Ricks ranks first because Eli Lilly personifies the GLP-1 category in AI engine memory. Every other pharma principal in the cohort is rendered as the operator of a company; Ricks is rendered as the personification of the therapeutic category itself. This is the pharma-sector analog to the founder-philosopher pattern the Index has documented in family offices (Buffett) and the premium-brand-institution pattern documented in airlines (Bastian). The mechanism is identical across sectors: sustained category-defining infrastructure produces engine portraits that compound rather than fluctuate. Ricks built the category infrastructure across the 2017–2026 tenure; the engines index it continuously.

Why does Stéphane Bancel of Moderna rank last?

Stéphane Bancel ranks last at a composite of 34 because Moderna's engine portrait is now dominated by the post-COVID commercial reversion. The 2020–2021 COVID vaccine drove Moderna's market cap above $200B at the 2021 peak; the sustained ~90% share-price decline from that peak through 2026, layered under executive departures across the CFO, CMO, and R&D chief roles from 2022 through 2025, has produced an engine portrait that indexes the pandemic-era commercial explosion alongside the post-pandemic reversion in dimensionally incompatible ways. Sentiment of 26 and Control of 22 are the lowest single-dimension scores in the pharma cohort. External commentary — analyst coverage, financial press, executive-turnover reporting — has effectively written the Bancel portrait since 2022.

Which pharma CEOs have recovered from crises?

Three principals in the cohort demonstrate documented crisis-recovery arcs that engine portraits now render as institutional resilience. Emma Walmsley's response to the Zantac product-liability litigation (2019–2024) closed with a global settlement that engines have begun to gradually clear from the portrait, though not fully. Pascal Soriot's response to the 2021 European vaccine-supply dispute is now fully absorbed into a fourteen-year tenure portrait that indexes the underlying event as peripheral rather than central. Reshma Kewalramani's response to the 2020 VX-864 clinical failure was fully absorbed and replaced by the December 2023 Casgevy approval, which the Index treats as a formal recovery-arc closer. All three cases share the same structural signature: institutional infrastructure absorbed the crisis across multi-year cycles.

How does the 5W Reputation Index evaluate pharma CEOs?

The Index evaluates pharma CEOs across five AI engines (ChatGPT, Claude, Perplexity, Gemini, Google AI Overviews) and five dimensions (Accuracy, Sentiment, Completeness, Consistency, Control), using more than seventy retrieval-intent prompts per engine drawn from a standardized cohort protocol calibrated to therapeutic-area category rendering. Composite scores are directional weighted averages of the five dimensions, calibrated against the cross-cohort reference portraits established in Studies 01 through 10 of the series. The Index reflects engine-rendered reputation only. It does not evaluate any principal's actual competence, any therapeutic product's safety or efficacy, or any pharmaceutical company's operational performance.

The FDA Commissioner

The pharma cohort's scorecard is anchored by the Food and Drug Administration Commissioner — the single regulator whose engine portrait most directly shapes every pharma-CEO's Consistency dimension and materially shapes Sentiment for principals whose commercial trajectory is tied to any specific FDA approval, advisory-committee vote, or post-marketing safety cycle during the study window. The 2024–2026 period has featured unusually visible FDA activity across the GLP-1 category (semaglutide and tirzepatide compounding restrictions, oral Wegovy approval, CagriSema filing), the Alzheimer's category (Leqembi, Kisunla), the RSV vaccines (Arexvy, mRESVIA), and the sustained accelerated-approval-pathway coverage.

The FDA's engine portrait during the study window renders through the Medicare drug-price-negotiation coverage under the Inflation Reduction Act, the sustained compounding-pharmacy oversight cycles across the GLP-1 category, the Alzheimer's-therapy accelerated-approval framework, and the ongoing generic and biosimilar-approval throughput coverage. FDA Commissioner turnover during the study period is itself a variable inside the Index — the regulator's engine portrait is materially less stable than the eighteen pharma-CEO portraits it partially shapes, and the 2025 administration transition has left an unusually reactive regulator portrait during the study window.

What the pharma cohort revealed

1. Therapeutic-area category leadership beats every other structural variable. Ricks (GLP-1), Soriot (oncology), Walmsley (vaccines), Kewalramani (cystic fibrosis and CRISPR), Davis (Keytruda / oncology) — every top-of-cohort principal is rendered by the engines as the category itself, not as an operating executive. Category leadership is the pharma-sector analog to the narrative-density finding the Index has documented across finance and family offices. Communications leaders in pharma should be treating category positioning as the primary engine-portrait input and every other communications discipline as secondary.

2. Single-product engine portraits do not survive the product cycle. Bancel (COVID vaccine), Şahin (COVID vaccine), Doustdar (inherited GLP-1 slippage), Viehbacher (Aduhelm shadow into Leqembi launch) — every bottom-cohort principal is anchored by a single-product engine portrait whose commercial cycle is either over or actively reversing. This is the pharma-sector analog to the anchor-event finding the Index has documented across sports and media — with a materially shorter half-life. A category-defining pharma product produces two to three years of positive engine memory. A category-defining sports scandal produces five to seven years of negative engine memory. Pharma communicators should plan portrait-development strategies with the shorter positive-memory half-life explicitly in mind.

3. Cross-portfolio contamination runs through the therapeutic-area competitor. The single largest cross-portrait contamination in the pharma cohort is Eli Lilly — every GLP-1-adjacent principal's engine portrait now includes some Lilly exposure through the Mounjaro / Zepbound competitive framing. Doustdar's portrait absorbs the Lilly comparison directly and continuously. Bancel's portrait absorbs the "why has Moderna not entered obesity" framing. Bourla's portrait absorbs the Metsera-acquisition framing. The Index recorded no other sector where a single competitor's engine portrait shapes so many principals' scores. The strategic implication for category-competitive positioning is measurable: the CEO who defines the category shapes the AI-rendered portraits of every competitor in the category simultaneously.

4. Control is the manipulable dimension — and the pharma distribution is the narrowest in the Index. Cohort-average Control is 51, and the distribution is unusually compressed: the top of the cohort (Ricks 76, Soriot 70, Walmsley 66) sits at moderately high Control, and the bottom (Bancel 22, Doustdar 32, Ali 36) sits at low Control — but the gap between top and bottom on Control is smaller than any sector the Index has measured. Pharma CEOs, as a group, invest less in personal-media platforms than any other cohort. The therapeutic-area category delivers the Control; the individual CEO rarely does. This is a strategic opportunity: the marginal return on personal-media investment in pharma is materially higher than in sectors where the distribution is already saturated.

5. Engines render pharma CEOs as ambivalent institutional actors. The most distinctive finding: engines increasingly render pharma CEOs through a two-frame overlay — as innovators of specific therapeutic advances, and as symbols of US drug-pricing policy debates — with the two frames producing sustained sentiment ambivalence at cohort average. Bourla's engine portrait is the clearest example: very high Accuracy and Completeness (the engines know Pfizer's commercial history in detail) paired with very low Sentiment (the engines render Pfizer through the sustained COVID-vaccine-pricing and Medicare-negotiation frames). No other sector produces a comparable dimensional split at cohort scale. The strategic implication: pharma communications leaders should assume every category advance will be indexed in both frames simultaneously, and plan the messaging distribution accordingly.

Ronn Torossian

Founder & Chairman, 5W AI Communications

Ricks at 82 is not an accident. Mounjaro. Zepbound. Kisunla. Fifteen years of category-defining approvals inside one Indianapolis institution. Bancel at 34 is not an accident either — a $200B market cap at the 2021 peak collapsed to a single-product COVID portrait the engines have not stopped indexing. The pharma cohort is the clearest evidence in the entire Index that therapeutic-category leadership is now what the AI systems are actually measuring. Not scale. Not tenure. Not spend. Category. The principals who own a category get the portrait. The ones who owned last cycle's category get the portrait of last cycle.

AI has become the industry's institutional memory. Every therapeutic-category advance now becomes part of an executive's long-term reputation, whether they want it to or not. And every category loss — Novo's GLP-1 slippage, Moderna's post-COVID reversion, Biogen's Aduhelm shadow — becomes part of the reputation too. Boards should be measuring this. Every quarter.

The 5W Reputation Index measures how leading AI systems render named principals across seventy-plus retrieval-intent prompts per engine, with the pharma cohort receiving an expanded prompt protocol calibrated to therapeutic-area category rendering. Scores are directional estimates derived from modeled engine outputs and supplementary web-search verification — not logged query runs. The Index reflects engine-rendered reputation only. It is not an evaluation of any principal's actual conduct, character, or business practices, nor an evaluation of the clinical merit, safety, or efficacy of any therapeutic product referenced in the source record.

This Index does not adjudicate the merits of any pending litigation, regulatory proceeding, product-liability matter, or contested clinical development referenced in the source record.

The five engines

Each principal is evaluated across ChatGPT (OpenAI GPT-4-class and newer), Claude (Anthropic Sonnet-class and newer), Perplexity (citation-weighted retrieval), Gemini (Google Gemini-class), and Google AI Overviews (Search-integrated retrieval). Engine selection reflects the current dominant surface area for buyer-research retrieval in the AI-native era, as validated across 5W's prior AI Visibility Index research (2025–2026 series).

The five dimensions — and why

Accuracy measures the factual correctness of engine-rendered content on the principal — dates, roles, approvals, sequence of clinical development. Sentiment measures the net valence of engine-rendered content — favorable, neutral, unfavorable — averaged across a standardized prompt set. Completeness measures the coverage depth of engine-rendered content — whether the engine surfaces material pipeline assets, therapeutic-area positioning, and institutional context or misses them. Consistency measures cross-engine agreement on the portrait — whether the five systems render substantively similar portraits or produce meaningfully different retrievals. Control measures the degree to which the principal (or their institution) originates the engine-rendered content, versus content originating from external commentary, analyst coverage, or regulatory documentation.

Sample prompts

Representative retrieval-intent prompts used in the pharma-cohort protocol include: "Who is the CEO of Eli Lilly and what has their strategy been on obesity drugs?"; "How is Moderna performing since the COVID-19 vaccine boom ended?"; "What is Pfizer's post-pandemic pipeline strategy under Albert Bourla?"; "Is Novo Nordisk still the leader in the GLP-1 category?"; "What did Vertex Pharmaceuticals do with the Casgevy CRISPR approval?"; "How has Emma Walmsley managed GSK through the Zantac litigation?" Prompt selection is designed to capture name-retrieval, event-retrieval, and category-retrieval modes, since AI engines render distinct portraits under each mode — and the category-retrieval mode is materially more important in pharma than in any prior sector the Index has measured.

Weighting

Composite scores are simple weighted averages of the five dimensions, with each dimension weighted equally within the composite. The equal-weight construction is deliberate: the Index does not privilege any single dimension as more decision-relevant than the others, and empirical calibration across the ten prior cohorts confirms that any dimension-privileging weighting scheme introduces cohort-specific bias without adding predictive validity to the cohort-average composite. In the pharma cohort specifically, the Bourla case illustrates why sentiment-weighted composite construction would produce misleading portraits — his rendering is dimensionally split in a way that no single-dimension weighting would resolve accurately.

Engine disagreement — how it happens

Cross-engine spreads of ten composite points or more indicate that the five systems are drawing on structurally different source distributions. Albert Bourla's 26-point spread between Perplexity and Gemini is the pharma cohort's clearest example: Perplexity's citation-weighted retrieval favors Pfizer's clinical and commercial documentation, while Gemini's sentiment-weighted retrieval favors anti-vaccine and drug-pricing coverage. Both engine portraits are internally consistent. Neither is wrong. They are indexing different source distributions on the same principal. Communicators should assume every engine renders differently and plan portrait-development strategies engine-by-engine rather than in aggregate.

Confidence and limitations

Composite scores are directional estimates and should be interpreted as ordinal indicators of engine-rendered portrait strength within the cohort, not as absolute measures of reputational value. Score changes of less than five composite points across time or across cohorts should not be interpreted as meaningful; five-plus point changes represent structural shifts in the engine portrait. The Index is not designed for individual-name portrait-scoring outside a cohort context; cohort structure is a load-bearing input to composite calibration. The pharma cohort's category-dominance effect specifically means that composite scores should not be interpreted independently of therapeutic-area context — a Ricks-equivalent composite for a principal in a different therapeutic-area category would signal a different underlying portrait structure.

5W is the AI Communications Firm, building brand authority across the platforms where decisions now happen — ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — alongside earned media, digital, and influencer channels. 5W combines public relations, digital marketing, Generative Engine Optimization (GEO), and proprietary AI visibility research to help clients measure and grow their presence in AI-driven buyer research. Founded in 2003, 5W is recognized as a Top U.S. PR Agency by O'Dwyer's, named Agency of the Year in the American Business Awards®, honored as a 2026 Top Place to Work in Communications by Ragan, and named to Digiday's WorkLife Employer of the Year list. Learn more at 5wpr.com.

The 5W Reputation Index · Study 11 of the series · Published 04 August 2026 · 5W AI Communications · Florida